John A. Bittl

John A. Bittl

Auto-generated profile, based on publicly available information

John A. Bittl

Scientific Publications Committee, American College of Cardiology, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 1995 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JBJohn A. Bittl
John A. Bittl
JSJohn Strony
John Strony
JBJeffrey A. Brinker
Jeffrey A. Brinker
WAWaqar H. Ahmed
Waqar H. Ahmed
CMClyde R. Meckel
Clyde R. Meckel
BABurt Adelman
Burt Adelman
Heparin is often administered during and after coronary angioplasty to prevent closure of the dilated vessel. However, ischemic or hemorrhagic complications occur in 5 to 10 percent of treated patients. We studied whether these complications could be prevented when the direct thrombin inhibitor bivalirudin (Hirulog) was used in place of heparin.

1 December 2001 in American Heart Journal
Verified
Journal Article
Closed access
JBJohn A. Bittl
John A. Bittl
BCBernard R. Chaitman
Bernard R. Chaitman
FFFrederick Feit
Frederick Feit
WKWilliam Kimball
William Kimball
ETEric J. Topol
Eric J. Topol

1 November 1992 in JACC
Verified
Journal Article
Closed access
MHMaribeth Hourihan
Maribeth Hourihan
SPStanton B. Perry
Stanton B. Perry
VMValerie S. Mandell
Valerie S. Mandell
JKJohn F. Keane
John F. Keane
JRJonathan J. Rome
Jonathan J. Rome
JLJames E. Lock
James E. Lock

24 October 1996 in New England Journal of Medicine
Verified
Journal Article
Closed access
JBJohn A. Bittl
John A. Bittl
The goal of therapy in patients with coronary artery disease is to alleviate symptoms of angina and reduce the risk of death or nonfatal myocardial infarction. Although coronary angioplasty immediately reduces anginal symptoms in almost all patients who undergo it, its use is associated with death or nonfatal myocardial infarction in about 5 percent of patients18 and with restenosis requiring repeated angioplasty or bypass surgery in about 30 percent.36,9 Recently, several clinical trials have shown that the implantation of coronary stents5,6 or treatment with blockers of platelet glycoprotein IIb/IIIa receptors1012 reduces the occurrence of acute . . .

1 April 1993 in JACC
Verified
Journal Article
Closed access
JBJohn A. Bittl
John A. Bittl
TRThomas J. Ryan
Thomas J. Ryan
JKJohn F. Keaney
John F. Keaney
JTJames E. Tcheng
James E. Tcheng
SEStephen G. Ellis
Stephen G. Ellis
TSTimothy A. Sanborn
Timothy A. Sanborn

4 June 2013 in Circulation
Verified
Journal Article
Closed access
JBJohn A. Bittl
John A. Bittl
YHYulei He
Yulei He
AJAlice K. K. Jacobs
Alice K. K. Jacobs
CYClyde W. Yancy
Clyde W. Yancy
SNSharon-Lise T. Normand
Sharon-Lise T. Normand
Background—: Several randomized clinical trials support the use of coronary artery bypass grafting (CABG) for patients with unprotected left main coronary artery disease. Studies suggesting the equivalence of percutaneous coronary intervention (PCI) with CABG for this indication indirectly support the 2011 American College of Cardiology Foundation/American Heart Association Class IIa recommendation for PCI to improve survival in patients with unprotected left main coronary artery disease. We tested whether bayesian approaches uphold the new recommendation. Methods and Results—: We performed a bayesian cross-design and network meta-analysis of 12 studies (4 randomized clinical trials and 8 observational studies) comparing CABG with PCI (n=4574 patients) and of 7 studies (2 randomized clinical trials and 5 observational studies) comparing CABG with medical therapy (n=3224 patients). The odds ratios of 1-year mortality after PCI compared with CABG using bayesian cross-design meta-analysis were not different among randomized clinical trials (odds ratio, 0.99; 95% bayesian credible interval, 0.67–1.43), matched cohort studies (odds ratio, 1.10; 95% bayesian credible interval, 0.76–1.73), and other types of cohort studies (odds ratio, 0.93; 95% bayesian credible interval, 0.58–1.35). A network meta-analysis suggested that medical therapy is associated with higher 1-year mortality than the use of PCI for patients with unprotected left main coronary artery disease (odds ratio, 3.22; 95% bayesian credible interval, 1.96–5.30). Conclusions—: Bayesian methods support the current guidelines, which were based on traditional statistical methods and have proposed that PCI, like CABG, improves survival for patients with unprotected left main coronary artery disease compared with medical therapy. An integrated approach using both direct and indirect evidence may yield new insights to enhance the translation of clinical trial data into practice.